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Background: Diagnosis and treatment of bloodstream infections (BSI) are often hampered by the delay in
obtaining the final results of blood cultures. Rapid identification of pathogens involved in BSI is of great importance
in order to improve survival of septic patients. Beacon-based fluorescent in situ hybridization (hemoFISH® Gram
positive and hemoFISH® Gram negative test kits, miacom diagnostics GmbH Düsseldorf, Germany) accelerates the
identification of most frequent bacterial pathogens of sepsis.
Results: In this study a total of 558 blood culture (377 blood culture positive and 181 negative) were tested with
the hemoFISH® method and the results were evaluated in comparison with the traditional culture based methods.
The overall sensitivity and specificity of the hemoFISH® tests were 94.16% and 100%, while, the PPV and NPV were
100 and 89.16%, respectively. As the hemoFISH® results were obtained within 45 mins, the time difference between
the final results of the traditional culture method and the hemoFISH® assay was about two days.
Conclusions: Considering the good sensitivity and specificity of the hemoFISH® assays as well as the significant
time saving in obtaining the final results (p-value 0.0001), the introduction of the system could be rialable in the
microbiology laboratories, even alongside the traditional systems.
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Sepsis is a serious clinical syndrome resulting from a
host’s systemic inflammatory response to infection [1].
When severe, it is associated with high mortality, greater
in patients with septic shock (40-70%), than in those
with sepsis alone (25-30%). The syndrome is nowadays
considered as a major international health care problem
[2,3]. Bloodstream infection is commonly associated with
the development of sepsis and requires microbiological
diagnosis usually performed by traditional culture, detec-
tion and identification of the causative pathogens of the
systemic inflammatory response syndrome (SIRS) [3-5].
However, culture routinely takes several days before a
positive result is available [6]. This gap between the ini-
tial clinical suspicion and the confirmation of infection
by culture results could result in a poor clinical outcome* Correspondence: carla.fontana@uniroma2.it
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reproduction in any medium, provided the orof the septic patient [7,8]. The long total turnaround
time (TAT) which characterizes traditional culture
methods encourages clinicians in empirical antimicrobial
therapy as a safety-first strategy. The delay in appropri-
ate antimicrobial therapy is associated with increased
mortality [7,8]. Therefore, there is an urgent need to
introduce techniques, with a reduced TAT, which allow
the clinicians to set therapeutic regimens in the earlier
stages of sepsis. Molecular methods seem to be an ap-
propriate choice, they are widely used in the diagnosis of
BSIs, along side to the conventional methods. Molecular
techniques are based on amplification of nucleic acids,
species-specific hybridization, microarray technology
and gene sequencing [9]. However, these techniques in-
volve significantly increased cost and technical complex-
ity, both of which are likely to hamper their adoption in
the laboratory routine in the clinical setting. Fluorescent
in-situ hybridization (FISH) technique is based on fluo-
rescently labelled oligonucleotide probes complementa-
rily binding to specific target sequences in the ribosomal
RNA of bacteria, yeasts or other organisms. The most
commonly used target for FISH in prokaryotes is 16Sral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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gions. However, the 23S rRNA in prokaryotes and the
18S and 28S rRNA in eukaryotes, as well as mRNA have
also been used as FISH targets [10]. Since the ribosomes
are found in a large number in active multiplying bac-
teria, especially in the log phase of bacterial growth, the
amplification step is not required. Target sequences will
be presented naturally in the bacteria in a concentration
high enough to enable visual detection of the specific
fluorescent signal. FISH was first applied for detection of
prokaryotes by environmental biologists for analysis of
microbial communities. The method was soon intro-
duced to medical microbiology and ever since used in
various fields of diagnostics of human infectious dis-
eases, with emphasis on situations when a speedy identi-
fication is crucial or the pathogen is difficult to culture:
sepsis, meningitis, endocarditis, respiratory tract infec-
tions, especially those of cystic fibrosis patients, screen-
ing for intrapartum Streptococcus agalactiae carriage,
diagnosis of zoonotic infections such as those caused by
Brucella and Francisella [11-17]. Miacom® diagnostics
GmbH has combined the classical FISH technology with
the usage of fluorescently labelled DNA-molecular bea-
cons as probes, making it an easy procedure known as
the beacon-based FISH (bbFISH®) technology [18]. It is
now possible, for the first time, to use specific probes
against a wide variety of clinically relevant bacteria
working directly on blood culture. The probes enter the
cells, hybridize to their specific targets, making the cells
visible using a fluorescence microscope. In order to assess
the possible benefits of the introduction of such technol-
ogy into the laboratory routine, we evaluated in the
present study the performance of the bbFISH® (hemo-
FISH® Gram positive and hemoFISH® Gram negative) in
comparison to the conventional culture of bacteria from
positive blood culture vials in febrile patients. The study
was conducted independently in two Italian centers: Poly-
clinic of Tor Vergata in Rome and Polyclinic Ospedale
G.B. Rossi in Verona. We have also examined the hemo-
FISH® test and the conventional identification assay’s total
turnaround time (TAT) performance.Results
Blood culture results
In this study 558 consecutive samples were tested: 377
positive and 181 negative. The Hospital of Verona proc-
essed 243 blood culture (88 negative and 155 positive)
while the Hospital in Rome analysed a total of 315 blood
cultures (93 negative and 222 positive). 393 were the iso-
lates (239 Gram-positive and 153 Gram-negative and
one yeast) identified by conventional system (Vitek 2
System), including those from 16 mixed blood cultures
(those which contain two isolates).hemoFISH® performances
The test works equally well in both centers being the
overall performances substantially similar. The hemo-
FISH® test correctly identified 364/393 isolates, showing
an overall agreement of 92.6% with the culture method.
If the performances were considered referred to the
specimens (not the isolates) 355/377 positive specimens
were identified by hemoFISH® (94.16%). The sensitivity,
the specificity the PPV and NPV were 94.16, 100, 100
and 89.16, respectively.
The individual Kit performances were as follows:
The hemoFISH®Gram negative panel correctly identi-
fied 143/153 (93.6%) of the Gram-negative for which a
specific probe was present in the Kit (59 Escherichia coli,
26 Klebsiella.pneumoniae, 4 Proteus mirabilis, 2 Proteus
vulgaris, 4 Salmonella spp, 5 Serratia marcescens, 14
Pseudomonas aeruginosa, 12 Acinetobacter spp, 4 Steno-
trophomonas maltophilia and 1 Haemophilus influenzae)
(Table 1). Two K.pneumoniae and one P.mirabilis were
identified only at the genus level as Enterobacteriaceae
spp (Table 1). Other Gram-negatives, for which there
were no specific probes on the panel, yet belonging
to the Enterobacteriaceae group, such as Klebsiella oxy-
toca, Enterobacter aerogenes and Enterobacter cloacae,
were correctly identified as Enterobacteriaceae spp. One
Pasteurella multocida (for which no specific probe was
present on the hemoFISH Gram negative panel) was
misidentified as Enterobacteriaceae spp (Table 1).
Eleven Acinetobacter baumannii and one Acinetobac-
ter lwoflii were identified as Acinetobacter spp. A mis-
identification was assigned to Aeromonas veronii, which
was improperly identified as Enterobacteriaceae spp
(Table 1).
Five specimens (2 Bacteroides fragilis, 2 Burkholderia
cepacia and 1 Rhizobiom radiobacter) were identified by
the traditional method, but they only gave a signal with
the positive control using the miacom test (Table 1). No
probes for these species are included in the test panel so
these results are conform with miacom’s claims.
The hemoFISH®Gram positive panel correctly identified
221/239 Gram-positive isolates (92.5%) (Table 1). Particu-
larly, a total of 130 coagulase negative staphylococci
were identified as Staphylococcus spp (the staphylococci
identification obtained using Vitek 2 system were: 70
Staphylococcus epidermidis, 23 Staphylococcus hominis,
22 Staphylococcus haemolyticus, 4 Staphylococcus warneri,
8 Staphylococcus capitis, 1 Staphylococcus auricolaris, 1
Staphylococcus saccharolyticus, 1 Staphylococcus saprophy-
ticus) while one sample positive for Staphylococcus cohnii
was not identified. 16 samples, positive per Staphylococcus
aureus, were correctly identified (Table 1).
Looking at the streptococci, 30/32 samples were cor-
rectly identified as Streptococcus spp (19 Streptococcus
mitis, 1 Streptococcus bovis, 2 Streptococcus oralis, 4
Table 1 hemoFISH Gram positive and Gram negative panels performances in identifying Gram-negative and
Gram-positive in comparison with Vitek 2 system
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Total 393 364 8 21
CoNS# = Staphylococcus coagulase negative, namely: S.capitis, S.hominis, S.haemolyticus, S.warneri, S.auricolaris, S.saccarolyticus, S.cohnii; & = Staphylococcus spp;
^ = Streptococcus spp; ° misidentified as E.faecium; § aspecific signal on green channel (eubacterial probe); * = Enterobacteriaceae spp; a = Salmonella spp;
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while among 5 specimens positive for Streptococcus
pneumoniae, 3 were identified as Streptococcus spp
(albeit no signal was evidenced with specific probe inS.pneumonie well) and 2 were not identified (only the sig-
nal with the eubacterial probe was recorded) (Table 1).
Enterococci were detected in a total of 41/44 speci-
mens, two Enterococcus raffinosus were not identified
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hemoFISH as Enterococcus faecium (Vitek 2 system
identified: 19 Enterococcus faecalis, 22 E.faecium, 2 E.
raffinosus and one E.gallinarum) (Table 1).
Eight specimens resulted positive for Microcococcus
spp, namely 4 Micrococcus luteus and 4 Micrococcus
lylae, of these, two (those positive for M.luteus) gave a
positive fluorescent signal on the Staphylococcus spp
well (recorded as misidentifications), the remaining 6
were not identified (Table 1).
Among the Gram-positive bacilli: two Corynebaterium
spp and two Bacillus spp were identified in four different
specimens by Vitek 2 (one Corynebacterium amycola-
tum, one Corynebacterium spp, one Bacillus cereus and
one Bacillus spp). Identification by hemoFISH® failed for
all of them (neither the signal for the positive control
was detected). While the hemoFISH® correctly identified
three Clostridium perfringens (Table 1).
One sample containing Candida did not yield a spe-
cific signal with any of the hemoFISH® probes but was
clearly visible via auto fluorescent signals on all fields.
A total of 29 specimens were not identified (21 strains)
or misidentified (8 strains) by the hemoFISH® test
(29/393; 7.4%). The global performances recorded with
the hemoFISH panels, in comparison with those identi-
fied by Vitek 2 system, are summarized in the Table 1.
The overall concordance between traditional culture
and hemoFISH® for the negative samples was 100%, no
fluorescent specific signal was recorded on 181 negative
blood cultures processed.
The average TAT from the hemoFISH® system and the
one obtained using traditional culture methods as well
as the Δ (means the difference in time to achieve a final
result) between the two system in both hospitals are
consistently different as reported in Table 2. The results
were available sooner using the hemoFISH® assay (mean
value 5.2) compared to the conventional assay (mean
value 43.65) expressed also by a p value of 0.001
(Table 2). The Verona data was obtained calculating the
work-flow on 5 days open laboratory. From all blood
cultures, the growth of microorganisms was obtained
after an incubation of 18-24 h and identification to the
family, genus or species level was achieved after anotherTable 2 The average time in obtaining results (express in TAT
within the two hospitals
Turn around time expressed in hours Hospital of Rome
Average TAT bbFish® (h) 8.9 (range 30 min-17,2H)
Average TAT of traditional culture method (h) 38.8
Two tailed p-value 0.0
Δ (earlier diagnosis) (h) 29.9
Δ = means the difference in time to achieve a final result.day, except for 16 samples, which contained more than a
microorganism and subcultures were required with a
delay of one more day. For this reason, the average TAT
obtained using traditional culture methods is 43.65 h.
hemoFISH® was performed in the same blood cultures,
with an average TAT of 5.2 h. The Δ TAT between the
two systems is 38.45 h, with a hemoFISH® time savings
of two days (compared with conventional laboratory
identification). hemoFISH® provides a same-day identifi-
cation of the majority of microorganisms and the turn-
around time is considerably lower than microbiological
culture.
Discussion
BSI, is a serious and life-threatening condition, rapid
diagnosis of BSI and identification of the pathogenic mi-
croorganisms are needed to improve the patient out-
come [5,8]. Blood culture is still currently considered the
“gold standard” in BSI diagnosis [8]. However, culture
assays require a long time to achieve a final result [19].
On the contrary examination of positive blood cultures
with specific molecular techniques based on the micro-
scopic morphology of the detected microorganisms
enables rapid and specific determination of sepsis patho-
gens, enhancing early adequate therapy and improving
prognosis of the patients [18-20]. A timely reporting of
results of a Gram stain of blood cultures to the physician
already showed a decrease in mortality [20]. If the com-
munication of a Gram stain result is combined with a
presumptive diagnosis of the pathogens involved in BSI
the clinician could more appropriately target the ther-
apy. To achieve this we find plausible to put the FISH
methodologies into a routine use in our laboratories.
The results of our work, aimed at the evaluation of the
bbFISH technology in comparison with the traditional
culture techniques, confirm the diagnostic usefulness of
this system. This test presents not only an excellent sen-
sitivity and specificity, but also a greatly reduced TAT.
Laboratory TAT is a reliable performance indicator,
which measures the laboratory’s efficiency in producing
its results [21-23]. The TAT is commonly defined as the
time elapsed between ordering a laboratory test and the
reporting of the results. In this study, the TAT was) of bbFISH® versus traditional culture methods in and
Hospital of Verona Mean value between the two hospitals
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flagged positive in the BacT/ALERT 3D® system to when
the final verification of the result was reported
(either by the identification of the microorganisms using
the hemoFISH® assay or the conventional culture assay),
this just to underline the advantage in using rapid detec-
tion assays compared to traditional systems, but avoiding
any other interfering parameters not strictly imputable
to the laboratory work flow. Our findings also underline
how different workflows in microbiology laboratory are
and how these can affect the TAT. The delay caused in
TAT is primarily due to the pre- and post-analytical
phases. The most common reasons for this delay were
found to be the order processing time, the laboratory ex-
cessive queue and the instruments times [22,23]. A huge
impact on TAT, particularly in analytical phase, was also
due to the choice of laboratory procedures. Recently,
many publications have underlined the usefulness of
“rapid methods” either PCR-based or those using the
newly introduced technology of matrix-assisted laser de-
sorption/ionization time-of-flight mass spectrometry
MALDI-TOF (MS) in diagnosing blood stream infec-
tions [24-26]. Moreover, delays in the reporting the tests
results were generally linked to the practice of interrupt-
ing the workflow over the weekend and during the holi-
days. Our study, in fact, showed that the main impact in
reducing the TAT is indeed in the laboratory itself,
where these interruptions were longer (Verona Hospital
than the Rome Hospital). No less important is the pres-
ence of skilled personal in the laboratory and their im-
pact on reporting time, as demonstrated by the TAT
recorded in the hospital of Rome. This laboratory realis-
tically reported the timing by performing hemoFISH®
tests even with those specimens processed in delay, due
to the lack of personnel in the laboratory (i.e. on Satur-
day afternoons and Sundays). This fact has had a heavy
impact on the observed average TAT (8.9 vs 1.5). Faster
TAT is universally seen as desirable, as the more timely
and rapidly a testing is performed, the more efficient
and effective will be the treatment [22,27,28]. This in
turn can save not only time and money for the patient
and the hospital, but more importantly it can save lives,
reduce patient morbidity and help reducing the further
increase of antibiotic resistance as well as a long stay at
the hospital [19,20]. Thus system such as bbFISH tech-
nology which is easy to use, with a reduced TAT and
which does not require sophisticated and expensive
equipments (as MALDI TOF needs instead to) could be
placed in a profitable manner, especially in small labora-
tories as well as in the hub laboratories which receive
samples from other hospitals (in the latter in order to re-
cover the time lost in the specimens transportation).
The only improvement we can auspicate is the imple-
mentation of the bbFISH panels by the adding of otherspecific probes on the slide (such as those for identifica-
tions of Corynebacterium, Gram-negative anaerobe and
Microcococcus spp) in order to reduce the number of
pathogens not identified by the system. Considering our
29 strains (ten Gram-negative and 18 Gram-positive
bacteria and one yeast) for which the bbFISH failed the
identification, we have observed that most of them were
not identified because of the absence of a specific probe
(this is true for Gram-positive: Bacillus spp., Corynebac-
terium spp. and Micrococcus spp., but also for Bacter-
oides spp, Rhizobium spp, A.veronii and P.multocida
among the Gram-negative). The remaining (two S.pneu-
moniae, one S.cohnii, two E.raffinosus two K.pneumoniae
and one P.mirabilis) could be easily explained either by
the sensitivity of the system or by a possible misinter-
pretation of the reader and finally we cannot exclude the
possibility of a technical error in preparing the slide. In
order to determine if the probes did really miss the cor-
responding bacteria or if the procedure failed for some
other reason, bacteria would have to be retested from
pure culture. Unfortunately at the time of data analysis,
when these discrepancies were evidencied, we could
have not done it anymore because the isolates had been
discarded.
Conclusions
The bbFISH technology is a new successful molecular
assay, supplementing traditional approaches, speeding
up the diagnosis of bloodstream infections and identify-
ing the majority of most important sepsis pathogens.
This assay has the potential to provide timely and cost-
effective information on infection status, thus allowing
clinicians to make more informed decisions on appropri-
ate antibiotic therapy at an earlier stage than is possible
with culture-based approaches. Complications can be
avoided and hospital stay may so be reduced. The
bbFISH technology can be a good choice, in order to re-
duce the analytical phase of TAT, in those laboratories
in which, due to the high cost, technologies such as PCR
and MALDI TOF cannot be introduced.
Methods
Specimens
A total of 558 blood cultures from different patients were
included in this study. 299 were the samples processed and
recorded by the Microbiology laboratory of Foundation
Polyclinic of Tor Vergata and 259 by the Microbiology
laboratory of Policlinico G.B.Rossi- Azienda Ospedaliera
Universitaria Integrata-Verona. Both are teaching hospitals
in Rome and Verona, Italy, respectively. The blood cultures
included in the study were those consecutively collected
and delivered in each hospital in a three months period.
The blood specimens were collected in BacT/ALERT FN
Plus and BacT/ALERT FA Plus vials, which were incubated
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l’Etoile, France).
Hospital workflow
The Verona hospital microbiology laboratory is a 5 days
open laboratory, meaning that laboratory workflow is fully
covered by a microbiologist from 8.00 a.m. to 3.00 p.m.,
Monday to Friday, but it is off duty on Saturday afternoon
and on Sunday. While, the Rome laboratory has a working
time divided on 7 days, from 7.30 am to 8.00 pm, but the
microbiologist, on Saturday afternoon and on Sunday, is
not present.
Traditional routine methods on positive blood culture
vials
The Bact/Alert 3D® (bioMerieux) system was used for
blood culturing. A minimum of two culture vials per pa-
tient, one aerobic and one anaerobic, were filled directly
with blood according to the manufacturer instructions.
Growth of microorganisms was detected by the instru-
ment. Cultures were continued for 5 days. When blood
culture vials flagged positive, some microliters from the
vial were aliquoted aseptically for light microscopy.
Gram stain was performed using Previ Color (bioMér-
ieux) according to the instructions of the manufacturer
and for culturing on a variety of agar plates for different
growth requirements (Agar Chocolate, Columbia supple-
mented with 5% of sheep blood and Schaedler agar
incubated under aerobic, micro-aerobic and anaerobic
condition respectively) and further identified using the
VITEK 2® system (bioMerieux,). The cultivation and iden-
tification was performed by the same trained individuals.
Beacon-based fluorescent in-situ hybridization
(hemoFISH®)
Miacom’s molecular probes consist of a DNA sequence
folded into a hairpin-like structure that is linked to a
fluorophore on the 5′ end and to a quencher on the
3′ end. Such probes are also referred to as molecular
beacons. The DNA sequence is complementary to a
rRNA counterpart that is unique to the family, genus or
species level of a certain organism. Because each bacter-
ial cell includes more than 10,000 copies of rRNA, no
amplification step is necessary [29]. Each rRNA copy
with a bound beacon contributes to a fluorescent signal
and the cell can be detected as a shining object under a
fluorescence microscope. In addition to the fluorescent
signal the cells morphology can be examined to confirm
the result. Miacom’s hemoFISH® Gram positive and
hemoFISH® Gram negative panels were used to perform
the assay. Tests were run as soon as possible after the
blood culture vial turned positive and not later than
24 hours. On positive blood cultures, dependent on the
Gram strain result, either a Gram negative (hemoFISH®Gram negative panel) or a Gram positive panel (hemo-
FISH® Gram positive panel) was used. Negative blood
cultures were processed using both kits (the test kits
used for these studies were kindly supplied by miacom
diagnostics GmbH, Düsseldorf, Germany). Briefly, an ali-
quot from a positive/negative blood culture vial (which
was either the aerobic or the anaerobic vial but the first
which turned positive) was diluted in Clinical Sample
Buffer and applied, dried and fixed onto an 8 field glass
slides placed on a hotplate pre-warmed to 52+/−1°C.
Permeabilization of bacteria including treatment with
enzymatic Lysis Solution at 52+/−1°C followed by an
incubation in ethanol. Hybridization with DNA-molecular
beacon probes was carried out in a hotplate hybridization
chamber at 52+/−1°C followed by an incubation in a
Stop Solution bath for 1 minute. This step ensures that
all unbound beacons are pushed back into the closed
conformation. Slides were dried, covered with mounting
medium and evaluated under a fluorescence micro-
scope. Two filter sets are required. One detects the
probes labeled with ATTO550 (red channel, absorption
max 554 nm/emission max 576 nm), the other one
those labeled with FAM (green channel, absorption
max 494 nm/emission max 520 nm). Total turn-around
time of the hemoFISH® assay was approximately 45 mi-
nutes (15 min of hands-on time plus the time required
for microscopic observation). The list of fluorescently
labeled probes used for the strain identification is the
following: Enterobacteriaceae spp., E.coli, K.pneumoniae,
S.marcescens, P.mirabilis, P.vulgaris, Salmonella spp.,
P.aeruginosa, Acinetobacter spp., S.maltophilia, H.influ-
enzae (for the hemoFISH G(−) Panel) and Staphylococ-
cus spp., S.aureus, Streptococcus spp., S.pneumoniae,
S.pyogenes, S.agalactiae, C.perfringens, E.faecium, E.fae-
calis (for the hemoFISH G(+) Panel).
The first field of the slide serves as an intrinsic control
of the procedure. It contains a probe that detects most
Eubacteria, giving a positive signal only in the red channel.
When turning to the green channel, no fluorescence
should be visible. On the remaining fields, there might be
pairs of probes, labeled either with FAM or ATTO 550,
giving either a red or a green fluorescent signal when the
specific target is encountered. If a specific target is not en-
countered, the unbound probes are pushed back into the
initial closed conformation and no fluorescent signal is
generated. Due to the use of molecular beacons, the wash-
ing step, known to be a critical and error-prone step dur-
ing the FISH procedure, can be omitted.
Statistical analysis
For database processing, data from BacT/ALERT 3D®
and VITEK 2® system were downloaded as text files into
Microsoft Excel with subsequent transfer of it into a
Microsoft Access database for analysis. Final tabulation
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ation, including graphs, created in Excel. The compari-
sons between the two techniques are expressed as
proportions. Standard descriptive statistical methods
(such as mean) were calculated, and a comparison of
the proportions was performed using a two-tailed Chi
squared test. Differences were considered to be signifi-
cant for a p-value ≤ 0.05 [30].
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